Product Specifications Detailed Mechanism of Action AOD-9604 is designed to replicate the lipolytic C-terminal tail of growth hormone while excluding the sequence regions responsible for IGF-1 elevation and insulin antagonism
It is an unapproved investigational compound that did not complete clinical development, has not been authorized by Health Canada for any human or veterinary indication, and is not intended to diagnose, treat, cure, or prevent any disease
The influence on the BPC-157 dopamine system, in particular, may explain some of the behavioral effects observed in animal studies, including antidepressant-like and anxiolytic-like activities
Full name: 5-Amino-1-methylquinolinium
Its important to talk to your healthcare provider to make a plan that fits you
Anecdotal Evidence and Personal Experiences with BPC157 Anecdotal evidence, such as the experience of individuals who have taken BPC157 and reported improved symptoms, could be used to inform the design of a clinical trial, but it is essential to account for the possibility of placebo effects 6m40s